Aurinia Pharmaceuticals (AUPH) stock plummeted 13.46% in the pre-market trading session on Thursday, following the release of the company's fourth-quarter 2024 earnings report and forward guidance.
Despite reporting better-than-expected Q4 earnings and revenue, with EPS of $0.01 beating analyst estimates of a $0.02 loss and revenue of $59.87 million exceeding forecasts of $59.7 million, investors were seemingly unimpressed with the company's performance.
While Aurinia swung to a full-year 2024 profit of $5.8 million after reporting a loss in the previous year, the company's forward guidance for 2025 revenue of $250-$260 million appears to have fallen short of market expectations, potentially triggering the sharp sell-off.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。